Merck's stock surged 95% in one year, driven by cancer drug Keytruda and strategic acquisitions.
Merck's stock surged 95% in one year, driven by cancer drug Keytruda and strategic acquisitions. Pluang
Read the full story on Pluang → Opens the original article on news.google.comSummary aggregated from Pluang's public RSS feed. The full reporting belongs to Pluang — please read it on their site.